Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2001 1
2002 18
2003 17
2004 15
2005 18
2006 23
2007 20
2008 16
2009 21
2010 15
2011 24
2012 27
2013 20
2014 24
2015 26
2016 24
2017 15
2018 18
2019 16
2020 15
2021 6
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Results by year

Filters applied: . Clear all
Page 1
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE 2nd, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V. Parker S, et al. Among authors: pastan ih. Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649. Epub 2023 Feb 8. Sci Transl Med. 2023. PMID: 36753564 Free PMC article.
Immunotoxins for leukemia.
Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. Wayne AS, et al. Among authors: pastan i. Blood. 2014 Apr 17;123(16):2470-7. doi: 10.1182/blood-2014-01-492256. Epub 2014 Feb 27. Blood. 2014. PMID: 24578503 Free PMC article. Review.
A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR, Vallera DA, Ettestad B, Hallstrom C, Kodal B, Todhunter DA, Bendzick L, Hinderlie P, Walker JT, Pulkrabek B, Pastan I, Kratzke RA, Fujioka N, Miller JS, Felices M. Kennedy PR, et al. Among authors: pastan i. Front Immunol. 2023 Feb 22;14:1060905. doi: 10.3389/fimmu.2023.1060905. eCollection 2023. Front Immunol. 2023. PMID: 36911670 Free PMC article.
Immunotoxins: From Design to Clinical Application.
Kreitman RJ, Pastan I. Kreitman RJ, et al. Among authors: pastan i. Biomolecules. 2021 Nov 15;11(11):1696. doi: 10.3390/biom11111696. Biomolecules. 2021. PMID: 34827694 Free PMC article.
Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R, Onda M, Pastan I. Mazor R, et al. Among authors: pastan i. Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390. Immunol Rev. 2016. PMID: 26864110 Free PMC article. Review.
Advances in anticancer immunotoxin therapy.
Alewine C, Hassan R, Pastan I. Alewine C, et al. Among authors: pastan i. Oncologist. 2015 Feb;20(2):176-85. doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5. Oncologist. 2015. PMID: 25561510 Free PMC article. Review.
Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.
Zhan J, Lin D, Watson N, Esser L, Tang WK, Zhang A, Liu X, Hassan R, Gleinich A, Shajahan A, Azadi P, Pastan I, Xia D. Zhan J, et al. Among authors: pastan i. Cancer Res Commun. 2023 Feb 1;3(2):175-191. doi: 10.1158/2767-9764.CRC-22-0306. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968141 Free PMC article.
Immunotoxin therapy of cancer.
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Pastan I, et al. Nat Rev Cancer. 2006 Jul;6(7):559-65. doi: 10.1038/nrc1891. Nat Rev Cancer. 2006. PMID: 16794638 Review.
350 results